EMEA draws up code of conduct for post-authorisation studies
This article was originally published in SRA
The European Medicines Agency has drawn up a code of conduct to help guarantee high standards, scientific independence and transparency in postauthorisation studies conducted under the EU’s pharmacoepidemiology and pharmacovigilance project (ENCePP).
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.